Anson Funds Management LP Sellas Life Sciences Group, Inc. Transaction History
Anson Funds Management LP
- $767 Million
- Q4 2024
A detailed history of Anson Funds Management LP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Anson Funds Management LP holds 1,192,266 shares of SLS stock, worth $1.44 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
1,192,266
Previous 793,835
50.19%
Holding current value
$1.44 Million
Previous $992,000
21.37%
% of portfolio
0.16%
Previous 0.12%
Shares
3 transactions
Others Institutions Holding SLS
# of Institutions
37Shares Held
6.49MCall Options Held
1.8MPut Options Held
49.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.77 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA734KShares$887,5900.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il485KShares$587,2330.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$520,7450.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$373,2433.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.9M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...